Joint replacements are the #1 expenditure of Medicare. The process of approving these medical devices is flawed according to the Institute of Medicine. It is time for patients' voices to be heard as stakeholders and for public support for increased medical device industry accountability and heightened protections for patients. Post-market registry. Product warranty. Patient/consumer stakeholder equity. Rescind industry pre-emptions/entitlements. All clinical trials must report all data.
Please share what you have learned!
Twitter: @JjrkCh

Saturday, October 19, 2013

Apply for this Patient Advocate Scholarship by November 1



 Apply for a scholarship to the 2013Lown Conference!    FiDA highlight






We are excited to announce that we have scholarship funding to help bring  medical students, residents, nurses and nursing students, community organizers, civic leaders, patients, and patient advocates to the 2013 Lown Conference - apply now
The conference is happening on Boston on December 3rd and 4th. You should read the full program, but here’s a refresher on the major goals of this year’s conference:
               Creating a new conversation among clinicians, patients, and civil society about the purpose of medicine and the health care system
               Understanding overuse as a moral and spiritual problem
               Recognizing that a better world is possible
               Envisioning health and health care 25 years from now.
We will also have working group meetings on December 5, the day after the conference, covering Medical Education, Public Engagement, International Collaboration, the Choosing Wisely campaign, and Setting the Research Agenda. If you are interested in participating in one of these working groups, please email us for more information at info@lowninstitute.org, and watch this blog for more details on the different working group agendas!
If all of that sounds exciting and informative, but you’re unsure of how to pay for travel, this is your opportunity! The scholarships will provide reimbursement (up to $1200) to cover travel and lodging for the conference. We are committed to using these scholarships to bring a wide range of voices and perspectives to the conference, and we know it will be a better event with representation from all groups concerned with reducing overuse in medicine.
If you’re interested, apply here by 5pm Eastern time on November 1, 2013. (That’s only two weeks from tomorrow!) We are only able to offer a limited number of scholarships, but will accommodate as many applicants as possible. We will notify recipients by email.  
And finally, please share this information with your colleagues, students, and anyone else who you think would benefit from participation in what promises to be an incredible conference!

Saturday, October 5, 2013

Exposed! : Secret Medical Device Payments to Doctors




The Women's Health Activist
September/October 2013
By Wells Wilkinson  FiDA highlight
On August 1, 2013, a new law went into effect that’s intended to protect patients and improve the public perception of medicine and the health care system. No, it’s not the new health care system, sometimes called “Obamacare.” But it was enacted as part of health care reform. The Physician Payments Sunshine Act (PPSA), originally proposed by Senators Chuck Grassley (R-IA) and Ed Kohl (D-WI), is intended to disclose any conflicts of interest arising from drug and device industries’ financial relationships with, or marketing to, physicians.
Lead legislative sponsor and champion Sen. Grassley praised the final implementation of the PPSA, saying: “Disclosure brings about accountability, and accountability will strengthen the credibility of medical research, the marketing of ideas and, ultimately, the practice of medicine.”1
The law creates the “Open Payments Program,” which requires the drug and device industry to record, and report to the federal government, nearly every payment or gift to any doctor or teaching hospital. The Federal government will make this information public in a searchable on-line database beginning on September 30, 2014; the database will be updated by June 30th each year thereafter.
The Open Payments system’s on-line information will be rich in details including the doctor’s name and office address, the amount and date of the payment, and a description of what the payment was for. It will also include any in-kind services, such as help doing research or writing a manuscript. And, any specific drugs or devices associated with this payment must also be reported and disclosed to the public.
Consumers will be able to look up “Doctor Jones” at his or her office address and see all the payments and nearly all of the gifts or meals their doctor’s received. Is your doctor a high-paid consultant? Does he or she get paid to give promotional talks to other doctors about a particular drug? If so, which drugs? Is your doctor collaborating with any companies to research and develop new products?
Some of the interactions between doctors and the drug industry are reasonable; some might argue they are even necessary, given the chronic lack of Federal financial support to develop new drugs or devices. But there are many gifts that are clearly designed to influence providers to use or recommend specific drugs or devices — and that’s not okay. Doctors should make health care recommendations and decisions based on what’s best for the patients and not the benefits they get from drug and device manufacturers.
Advocates have long sought to make this information public due to concerns that the vast majority of these financial relationships boil down to one thing — highly sophisticated forms of industry marketing. Open Payments will also help consumers and the public see if their doctor has accepted tickets to concerts or sporting events from a drug company. Is the doctor letting one or more drug companies deliver lunch to their office staff? Has he or she let a drug or device company pay for any travel or lodging and, if so, where? Is the doctor going out to dinner at fancy restaurants on the manufacturer’s dime, to learn about a particular drug or device product?
Transparency, so what?
If you see your doctor’s name on the database, how can you be sure that his or her recommendations are based on best practice, not other motives? If your doctor is getting concert tickets, that’s clearly questionable. But what does it mean that your doctor is paid to speak about a drug? Many patients may find some of these relationships confusing, or even alarming. Patients will have to decide whether to discuss payments or other gifts with their doctors — not an easy task for any patient walking into their provider’s office.
Some kinds of gifts or payments — like tickets to entertainment events — are prohibited by law in some states. Others — like gifts, dinners, and travel expenses — are prohibited by internal policy at some academic medical centers that want to protect their medical students and patients from industry influence. But, most doctors have no external limits on the kinds of gifts they can accept, and that’s where transparency may have an effect. As Sen. Grassley states, “The lack of transparency regarding payments made by the pharmaceutical and medical device community to physicians has created a culture that this law should begin to change substantially.”2
Doctors may think twice about accepting gifts if they know their name will appear in the Open Payments online database.  This public transparency may cause them to think twice about accepting gifts, because they don’t want to explain to their patients or the public why they accepted $5,000 in lunches over a year from different drug companies, or received expensive travel to a conference held at a fancy resort. 
We know that limiting drug and device company gifts is good, because companies give out these gifts precisely because they work in encouraging doctors to use their drugs and devices. From big-ticket items (like expensive travel to an exotic location) down to small items (like free lunches or pens), gifts impact physician attitudes. Studies show that even small gifts, like coffee mugs, can increase a doctor’s positive feelings about a manufacturer and their products. Numerous studies show that, when doctors accept a gift (large or small) they then have feelings of obligation to the company that made the gift.3 Former drug industry salespeople report being trained to use this feeling to influence doctor’s to reciprocate and prescribe more of the company's products.4
Conversely, we know that limiting gifts can impact prescribing and make doctors more likely to prescribe older, more established (and more affordable) medications rather than the more expensive brand-name drugs promoted by gifts and industry marketing.5 In fact, one medical school found exactly that: doctors saw fewer salespeople once the institution banned industry from delivering free lunches to doctors. There’s some speculation that doctors have already started to reduce their interactions with drug company salespeople. A recent survey shows about a 4 percent drop in 2012 in the number of physicians who said they were willing to see drug industry salespeople.6
Perhaps most importantly, patients are skeptical about these kinds of gifts. A recent study showed that, when patients know their doctor receives gifts from the drug industry, they have less trust in their doctor and the drugs they prescribe.The Open Payments database will reveal the full range of financial relationships between doctors and industry. If the new program makes doctors less interested in accepting gifts, and/or meeting with company salespeople, it could have far-reaching impacts. Any effort to reduce the influence of profit-driven industry marketing on doctors, leaving them free to select drugs and devices based on science rather than marketing, is good for patient care — and is likely be rewarded with greater patient trust. What more could any doctor want? 
Wells Wilkinson is a Staff Attorney with Community Catalyst, a national, non-profit consumer advocacy organization that works in partnership with national, state, and local organizations, policymakers, and philanthropic foundations to ensure consumer interests are represented in communities, courtrooms, statehouses and on Capitol Hill. More information at: www.communitycatalyst.org.

References
1. Rep. Charles Grassley, Press Release: Physician Payments Sunshine Act Regulations Released,” Washington, DC: US House of Representatives, February 1, 2013. Available online at:  http://www.grassley.senate.gov/news/Article.cfm?customel_dataPageID_1502=44416; last visited July 15, 2013.
2. Rep. Charles Grassley, Press Release: Physician Payments Sunshine Act Regulations Released,” Washington, DC: US House of Representatives, February 1, 2013. Available online at:  http://www.grassley.senate.gov/news/Article.cfm?customel_dataPageID_1502=44416; last visited July 15, 2013.
3. Katz D, Caplan AL, Merz JF. “All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving,” Am J Bioeth 2010; 10(10):11–17.
4. Fugh-Berman A, Ahari S, “Following the script: how drug reps make friends and influence doctors,” PLoS Med. 2007; 4(4):e150. doi:10.1371/journal.pmed.0040150
5. King M, Essick C, Bearman P, et. al., “Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis,”  BMJ  2013; 346: f264, available at http://www.bmj.com/content/346/bmj.f264?view=long&pmid=23372175.
6. SK&A, Physician Access -- U.S. Physicians’ Availability to See Drug and Device Sales Reps, March 2013, available at http://engage.vevent.com/content/conf/docs/ec_1058/Physician_Access_1193785.pdf?__tkn__=1373054532_0c8a5a3098f85de093f319da3143fdb2a142b8d8410967000cc25d220989fb80&eid=1058&seid=429 registration required.
7. Green MJ, Masters R, James B, et. al., “Do gifts from the pharmaceutical industry affect trust in physicians?” Family Medicine 2012; 44(5):325-31, available at http://www.stfm.org/fmhub/fm2012/May/Michael325.pdf  


Friday, October 4, 2013

Defective Implants: Warranty?


Defective Machinery: Should Hip and KneeReplacements Come With Warranties?


By William Heisel  USC Annenberg – Reporting on Health
October 04, 2013  FiDA highlight


During my last eye exam, my doctor persuaded me to start wearing reading glasses. I should keep my regular pair for driving, watching football, and enjoying the films of John Cusack. But I should wear reading glasses for what I’m doing right now – writing this blog post.
When I received them, though, they were so powerful that I felt like I had knocked back half a bottle of vodka. I tried them for a few days but could never shake that shaky feeling. So I called the optometrist and, to my surprise, I was told just to bring them back in. They were under warranty and new lenses would be cut for me in a few days.
Now, imagine if that eye problem I had was a hip problem or a knee problem or just about any other part of my musculoskeletal structure. If a doctor inserted a hip replacement that didn’t end up working and actually made my life worse, I would be out of luck. Warranties – common in so many aspects of our lives – are not common in orthopedic devices.
And there’s a good case to be made that should be. Witness the massive recall of Articular Surface Replacement Hip Systems sold by DuPuy. The New York Times wrote recently:
The implants were recalled in 2010, but the documents show that as early as 2008 DePuy executives were told by a number of surgeons, including its own consultants, that the device appeared flawed. That was never disclosed to doctors who were putting the device into patients, nor were other unfavorable internal studies. By the time of the recall, the device had been implanted in about 93,000 patients around the world.
And no warranty. DuPuy has tried to make up for the problems by offering financial assistance for patients’ recall-related medical costs, according to company president Andrew Ekdahl.
But what about making it explicit up front – as with my glasses – that device failures within a certain timeframe should be automatically replaced or that a refund should be received?
The Consumers Union’s Safe Patient Project is making a push for warranties on hip and knee replacements. I met with their team during their state-hopping campaign this week, and they raise some good arguments, rooted in a Consumers Union review of replacement products. Their main points include:
                All major manufacturers have recalled a product or a line of products for defects over the last decade.
                Most hip and knee implants are allowed on the market without being reviewed for safety and effectiveness by the Food and Drug Administration.
                The cost for additional surgery and a replacement device is now largely paid by patients or their insurance companies, including Medicare.
                Revision surgery costs more, results in longer hospital stays, and can often lead to additional surgeries.
                An estimated 18 percent of hip replacements and 8 percent of knee replacements in the U.S. are for revisions, and the cost for these procedures is likely in the hundreds of millions of dollars per year.
The counter argument is also about costs. Were device makers to cover all costs for all device failures, they may be seriously hurt financially. Also, is there a reasonable expectation that a certain percentage of any product made and sold will fail and do consumers necessarily have a right to get a new one as a result? I used my glasses as an example at the beginning, but if the rechargeable battery in my iPhone fails (making my device useless) I’m out of luck.
I will explore warranties in future posts. Let me know your ideas, too. I’m at askantidote [at] gmail.com and on Twitter wheisel.



Explanthis (Joleen Chambers, FiDA) 
Another issue to consider is that currently there is no patient outcome registry.  Consider the thousands implanted with failed metal-on-metal hips and transvaginal surgical mesh.  Proprietary and profitable medical device companies either missed the signal of device failure or chose to ignore it.  The patient harm in the wake of these private businesses becomes a public health cost borne by all of us.  A warranty would be a simple signal to the company to balance patient safety with marketing and sales efforts.

Thursday, October 3, 2013

Held hostage by medical device cheerleader: Representative Erik Paulsen (R-MN)


Article by: KEVIN DIAZ , Star Tribune Updated: October 2, 2013 - 10:14 PM
FiDA highlight

WASHINGTON – A small group of rank-and-file House members trying to break through the impasse in the government shutdown revived talks on Wednesday aimed at repealing a health care tax that falls heavily on Minnesota’s medical device industry.
The effort is being led by Minnesota Republican Erik Paulsen, who has cast himself as the champion of an industry estimated to employ 35,000 in Minnesota. Paulsen said he discussed his proposal Wednesday with Republican House Speaker John Boehner hours before House and Senate leaders were scheduled to meet at the White House with President Obama.
“I said this can and should be part of the solution,” said Paulsen, one of about a dozen House Republicans who have signaled their willingness to drop GOP demands of defunding or delaying the Affordable Care Act, often called Obamacare, as a condition of keeping the government open.
Paulsen sponsored a measure to repeal the medical device tax as part of a GOP government funding proposal that got 17 Democratic votes over the weekend. The Democratic-led Senate stripped the language as part of a broader dispute over Republican efforts to derail the Affordable Care Act, which rolled out this week.
Minnesotans in Congress from both parties have been pressing to undo a $30 billion medical device tax levied under Obama’s health care overhaul. But the two sides have been unable to agree on a way to make up the lost revenue.
Now, with both sides looking for an end to the government shutdown, the repeal effort has been caught up squarely in the protracted politics of the standoff.
Democrats, including Minnesota Sens. Amy Klobuchar and Al Franken, have said they are unwilling to repeal the tax as part of any GOP funding measure that delays implementation of Obamacare as the price for keeping the government open.
“I continue to believe that the current continuing resolution is not the best place to work out a medical device tax repeal that the president would sign into law,” Franken said. “I think the surest way to quickly reopen the government is for the House to vote on the Senate-passed bill to fund the government at its current levels. But I will take a careful look at any proposal that emerges.”
Meanwhile, Republicans have used the issue to attack Minnesota Democrats who voted against the repeal of the medical device tax as part of a GOP funding measure that puts off the health care law.
Despite the discord, Paulsen said the repeal effort represents the best opportunity for compromise. “The number one provision in this entire debate that has brought the most bipartisan support is repealing the medical device tax,” he said. “So we’ve got an opportunity to make that the linchpin as part of a solution.”
Paulsen said he has been in talks with a group of Republican and Democratic House members, including Wisconsin Democrat Ron Kind, an opponent of the medical device tax. Kind, however, has been working on a way to offset any lost revenues that might result.
Optimism from the industry
Industry leaders expressed guarded optimism about the new push on the medical device tax, which already has collected more than $100 million.
“There is reason for optimism that there is a critical mass and bipartisan support for repealing the tax,” said J.C. Scott, chief lobbyist for the Advanced Medical Technology Association.
The House voted last year to repeal the 2.3 percent excise tax on medical device makers like Minnesota-based Medtronic, which has said the tax could cost it $175 million annually. But efforts to win passage in the Senate have been stymied by Democratic concerns about losing one of revenue streams to pay for Obama’s 2010 health care law intended to cover some 40 million uninsured Americans. The repeal measure also has faced a White House veto threat.
White House officials contend that medical device makers will benefit from the new business created by the expansion of coverage to Americans who are now uninsured.
Where state’s senators differ
While Franken and Klobuchar have vowed to get the repeal through the Senate, they differ on a key sticking point: how to make up for the revenue.
Last year’s House-passed bill would have offset the lost taxes by shrinking insurance subsidies for low- and middle-income workers under the health care law. Franken said the GOP plan would undermine the goal of affordable health care.
Klobuchar said Wednesday that she is committed to repealing the medical device tax. However, she said, “the president has made clear that he will not accept changes to the Affordable Care Act as a condition for opening the government.” That doesn’t prevent a repeal in future negotiations, she said, adding that “the best way to get there is for the House to take up the Senate bill to reopen the government so we can have those negotiations.
Paulsen said House members are working on new revenue measures. “It’s definitely something that’s being conducted by rank-and-file members looking for a way out and a solution with bipartisan support,” he said.
Even if enough Democrats come on board, Paulsen’s greatest challenge may be convincing other Republicans.
“I would call it a win,” Paulsen said. “It would be a major accomplishment that helps the economy.”


explanthis
Oct. 3, 13
1:12 PM
The medical device industry is poorly regulated. I have been a patient advocate on the federal level for nearly 5 years, testifying at FDA meetings about the high rate of failure of implanted hips, knees and surgical mesh. The industry has fought UDI (unique device identification), legal protections for harmed patients, transparency of doctor/device mfg. financial relationships and independent outcomes registries to adequately inform patients and their providers. Right now, in WV federal court there are nearly 50,000 harmed women fighting for their civil rights and compensation for 'morbid disfigurement' from multiple manufacturers of surgical mesh. The 2.3% tax is warranted and capitulation to this entitled industry by our elected representatives is undemocratic. Research on 'Failed Implanted Medical Devices'.


Wednesday, October 2, 2013

Scotland takes action: patient harm from surgical mesh.


Oct 1st, 2013 | By Jane Akre | Category: Media Reports FiDA highlight and comment below

The Sunday Mail

Scotland is making changes in the way the public is warned about transvaginal mesh.
The Scottish Parliament set up a transvaginal mesh working group in May 2013. Last week the TVM working group met with the Minister for Health and Well Being.
Scotland’s Health Minister Alex Neil has ordered the National Health Service to warn women about transvaginal mesh surgery after a series of reports in the Sunday Mail about the “horrific complications” suffered by hundreds of patients.
“Officials will produce revised consent forms and information leaflets within two weeks. The move follows our campaign revealing how women have been crippled and maimed by polypropylene mesh implanted during surgery meant to help bladder and prolapse problems.”
Mr. Neil made the announcement with five mesh victims and vowed that all health boards will be asked to use these new forms. A leaflet will be given to all women considering surgery with mesh. The Sunday Mail reports it has received contacts from more than 300 people who tell “how their lives were destroyed by the implants.”
Ironically there have been only six reports of complications by doctors in Scotland to United Kingdom’s version of the FDA, the Medicines and Healthcare Regulatory Agency.
Neil says “clearly the system isn’t working. Doctors aren’t compelled to report adverse incidents to the MHRA.”
Anti-mesh campaigners are calling for an implant register to record procedures involving implantable medical devices such as mesh, breast implants and hip replacements. The European Union was recently rocked by the PIP breast implant scandal where a French manufacturer was using industrial grade silicone to fill breast implants. The government has had to step in and pay for implant removal surgeries.

Drs. Raz, Margolis Help
Dr. Michael Thomas Margolis of Bay Area Pelvic Surgery and Dr. Shlomo Raz, a urologist from UCLA added their comments to the proceedings. Dr. Margolis wrote a letter to Minister Alex Neil and DR. Raz commented by email.   Here is the letter.
Dr. Margolis is a surgeon in the area of female pelvic reconstruction. He’s been removing mesh implants since the mid 1990’s and now removes two a week. He reports complications include injuries to the bladder, bowel, blood vessels and vagina.
He told the parliament he’s treated “patients with vaginal mesh erosion, chronic complications of mesh including chronic infection, chronic scarring, chronic pain, morbid disfigurement and loss of function of the vagina.”  Many marriages are ended by the mesh issue, he says.
Dr. Raz reported that partial mesh removals do not work for pain “It must be removed completely. Ultrasound is the only test that shows mesh. No other imaging will show it.”
“In the last 6 years we have removed more than 500 mesh complications. 70% of the patients are improved or cured while 30% are permanent disabled from the mesh including vaginal pain, leg pain, pain during intercourse. We remove all the mesh. This is the only hope for patients with complications from mesh,” Dr. Raz wrote in an email.
The working group in Scotland is making positive progress, say advocates, as are colleagues in England that recently met with Lord Howe at Westminster in London. #
Learn More:
Facebook Scottish Mesh Survivorshttps://www.facebook.com/karen.neil.16503

http://meshmedicaldevicenewsdesk.com/media-reports/transvaginal-mesh-warnings-to-be-strengthened-in-scotland-at-the-urging-of-mesh-injured/


Joleen Chambers says:
Bravo Scotland! Valuing harmed patients and validating their stories by direct corrective action will save lives and the healthcare budget of your nation. In the U.S. the overly entitled medical device cartel is now holding our country hostage in a budget funding shut down to force changes in the Affordable Care Act to eliminate the paltry 2.3% tax. The U.S. FDA was the gold standard of regulation until it was infiltrated by industry influences, defunded to a level of irrelevance and ignored by legislators that could have progressively adapted laws to reflect the advancement of profiteering by this industry and updating the FDA/CDRH charter.

Saturday, September 28, 2013

Stents overused: criminal medical treatment?



By Peter Waldman, David Armstrong & Sydney P. Freedberg - Sep 25, 2013 9:01 PM PT
FiDA highlight

Then he went to see cardiologist Samuel DeMaio for chest pain. DeMaio put 21 coronary stents in Peterson’s chest over eight months, and in one procedure tore a blood vessel and placed five of the metal-mesh tubes in a single artery, the Texas Medical Board staff said in a complaint. Unneeded stents weakened Peterson’s heart and exposed him to complications including clots, blockages “and ultimately his death,” the complaint said.
DeMaio paid $10,000 and agreed to two years’ oversight to settle the complaint over Peterson and other patients in 2011. He said his treatment didn’t contribute to Peterson’s death.
“We’ve learned a lot since Bruce died,” Shirlee Peterson said. “Too many stents can kill you.”
Peterson’s case is part of the expanding impact of U.S. medicine’s binge on cardiac stents -- implants used to prop open the arteries of 7 million Americans in the last decade at a cost of more than $110 billion.
When stents are used to restore blood flow in heart attack patients, few dispute they are beneficial. These and other acute cases account for about half of the 700,000 stent procedures in the U.S. annually.
Among the other half -- elective-surgery patients in stable condition -- overuse, death, injury and fraud have accompanied the devices’ use as a go-to treatment, according to thousands of pages of court documents and regulatory filings, interviews with 37 cardiologists and 33 heart patients or their survivors, and more than a dozen medical studies.
’Marching On’
These sources point to stent practices that underscore the waste and patient vulnerability in a U.S. health care system that rewards doctors based on volume of procedures rather than quality of care. Cardiologists get paid less than $250 to talk to patients about stents’ risks and alternative measures, and an average of four times that fee for putting in a stent.
“Stenting belongs to one of the bleakest chapters in the history of Western medicine,” said Nortin Hadler, a professor of medicine at the University of North Carolina at Chapel Hill. Cardiologists “are marching on” because “the interventional cardiology industry has a cash flow comparable to the GDP of many countries” and doesn’t want to lose it, he said.
Stenting abuse is by no means the norm, but neither is it a rarity. Federal cases have extended from regional medical centers in Louisiana, Kentucky and Georgia to a top-ranked metropolitan hospital system in Ohio.
Asset Seizure
A doctor practicing at a hospital owned by the Cleveland Clinic, rated the premier heart center in the country by U.S. News and World Report, had his assets seized by federal agents in a stent investigation, according to federal court filings in April. The Clinic has not been accused of wrongdoing, and says it’s cooperating with the investigation.
Two out of three elective stents, or more than 200,000 procedures a year, are unnecessary, according to David Brown, a cardiologist at Stony Brook University School of Medicine in New York. That works out to about a third of all stents.
Brown said his estimate is based on eight clinical trials of 7,000 patients in the last decade, which he analyzed in the Archives of Internal Medicine last year. Two cardiology researchers who have studied the use of stents say the number could be as low as about half Brown’s estimate, and one said it is probably larger.
Costs, Risks
Even the low end of these estimates translates into more than a million Americans in the past decade with implants in their coronary arteries they didn’t need, said William Boden, chief of medicine at a Veterans Administration hospital in Albany, New York. Boden was the principal investigator of a 2007 study known as Courage that found stents added no benefit over medicines, exercise and dietary changes in stable patients.
Unnecessary stents cost the U.S. health care system $2.4 billion a year, according to Sanjay Kaul, a cardiologist and researcher at Cedars-Sinai Medical Center in Los Angeles. Patients who received them are living with risks including blood clots, bleeding from anti-clotting medicine and blockages from coronary scar tissue, any of which can be fatal, Kaul said.
Monica Crabtree died at age 64 after one of her arteries was torn in a stent procedure that led to infection, according to her widower, Gary Crabtree. He received at least $240,000 from a 2011 settlement of his lawsuit against her doctor, after a second cardiologist reviewed the case and told him the stent wasn’t needed. Crabtree choked up speaking about his late wife and showed pictures of their 47 years together.
Worried Shaving
“It wasn’t just a simple mistake,” said the retired auto worker in Largo, Florida. “If the stent was something she really needed, I could have handled it. But it was a total loss of life that didn’t need to happen.”
Jim Simecek, of Medina, Ohio, said he worries every morning that a nick from shaving could bleed out of control. Simecek, who works at a Ford dealership, said he has to take blood-thinning medicine for life to ward off clots in the six stents he received from a Cleveland-area cardiologist who’s under federal investigation for his stent work.
“It’s as if your heart was open and somebody was sticking a knife in,” said Rhonda McClure, 54, referring to eight stents she received from a Kentucky cardiologist who agreed in June to plead guilty to a federal Medicaid-fraud charge for falsifying records used to justify a stent he placed.
Patient Letters
Cardiac stents were linked to at least 773 deaths in incident reports to the U.S. Food and Drug Administration last year, according to a review by Bloomberg News. That was 71 percent higher than the number found in the FDA’s public files for 2008. The 4,135 non-fatal stent injuries reported to the FDA last year -- including perforated arteries, blood clots and other incidents -- were 33 percent higher than 2008 levels.
The FDA declined to comment on whether the reports were a cause for concern. It said adverse-event reports tied to medical devices have increased overall due to agency efforts. It also said the data can contain incomplete and unverified accounts from reporting parties.
More than 1,500 patients have gotten letters from hospitals since 2010 alerting them that their stents may have been unnecessary. In Philadelphia, the University of Pennsylvania Health System sent 700 such notices in April.
Stenting Decline
At least 11 hospitals have settled federal allegations of charging for needless stenting and other misdeeds in the catheterization labs where the procedures are performed. Federal probes of stenting practices continue in at least five states. In Louisiana and Maryland, cardiologists went to federal prison last year for implanting the devices and charging for them without medical justification. A third doctor has agreed to do time in a plea bargain.
“There is a huge financial incentive to increase the number of these procedures,” said Jamie Bennett, a former assistant U.S. Attorney in Baltimore who handled stent investigations. “The cases we have seen to date are just the tip of the iceberg.”
Since Boden’s Courage study, stenting procedures have declined by about 20 percent. Still, this July, a panel of experts convened by the American Medical Association and the Joint Commission, a hospital accreditor, named elective stenting as one of five overused treatments that too often “provide zero or negligible benefit to patients, potentially exposing them to the risk of harm.”
Better Choices
Doctors are using fewer stents and choosing more-appropriate patients than they were a few years ago, according to John Harold, president of the American College of Cardiology, the specialty’s main professional group. Harold said that “real-world clinical practice” and research indicates Brown probably overestimated how many people with coronary artery disease could be handled initially only with drug-based treatment.
He said there are examples of inappropriate use and the ACC is taking steps to “address and correct the imbalance” with treatment guidelines and by urging more hospital oversight. Cardiologists who’ve been accused of fraud or are serving prison time are “outliers” who don’t represent the “overwhelming majority.”
Lawyers for John McLean, a Salisbury, Maryland, cardiologist convicted of billing for unwarranted stenting, argued in a federal appeal last year that inappropriate usage is widespread and their client was prosecuted for behavior that’s the industry norm.
Lost Appeal
They cited a 2011 study in the Journal of the American Medical Association that found only half of elective stent procedures nationally were appropriate under usage guidelines written by societies of heart specialists. The study found 12 percent were inappropriate, and 38 percent fell into the uncertain category of the guidelines.
“The study demonstrated clearly that a large number of stable patients receive coronary artery stents that are later found to be inappropriate or questionable,” the appeal argued. “The same was true of the patients in Dr. McLean’s practice.” McLean’s appeal was denied in April. He is serving an eight-year sentence.
Elective-stent patients typically see rapid quality-of-life improvements, including in their ability to work and be active, according to Ted Bass, president of the Society for Cardiovascular Angiography and Interventions, whose members specialize in cardiac implants. The Courage trial found stents, compared to medication and lifestyle changes, were better at relieving chest pain for as long as two years after placement -- a benefit that ended by 36 months.
Profit Centers
First used in Europe in 1986, cardiac stents took off in the 2000s as cardiologists found them to be more effective in heart attacks than angioplasty. In that earlier technology, a small balloon is inflated to widen blood passages and then withdrawn. Stenting facilities, known as “cath labs,” spread at hospitals and became profit centers.
Hospitals receive an average payment of about $25,000 per stent case from private insurers, according to Healthcare Blue Book, a website that tracks reimbursements. The federal Medicare program pays less. Doctors who implant stents earn a separate fee that averages about $1,000 and ranges from $500 to $2,850, according to Medicare and Blue Book data.
The procedure typically involves inserting the stent with a catheter through a small incision in the groin area or wrist and snaking it through to heart vessels. It usually takes less than 45 minutes.
Kickbacks Alleged
Stony Brook’s Brown, and Boden, who led the Courage study, argue that many elective patients should be getting medical therapy before they risk stents. Only 44 percent try medication and lifestyle changes before stenting, a 2011 study in the Journal of the American Medical Association found.
At least five hospitals have reached settlements with the Justice Department over allegations that they paid illegal kickbacks to doctors for patient referrals to their cath labs. St. Joseph Medical Center in Towson, Maryland, paid the government $22 million without admitting liability.
Prosecutors alleged the hospital paid kickbacks to a practice co-founded by Baltimore cardiologist Mark Midei for stent referrals. His doctor’s license was revoked in 2011 when the Maryland Board of Physicians found he falsified records to justify unwarranted stents.
St. Joseph told 585 of its patients they may have received unnecessary stents. In May, 252 patients reached a settlement with the hospital under confidential terms, according to Jay D. Miller, an attorney for the plaintiffs.
Plea Agreement
The hospital settled the government’s case “to avoid the expense and uncertainty of litigation,” it said in a statement. Spokeswoman Julia Sutherland said the hospital declined to comment on any patient lawsuits.
In an interview, Midei denied he stented without medical need. He took issue with experts who deemed many of his stents needless, and said disagreement among cardiologists on cases is common. Midei was not a party to the federal settlement. The government has said its investigation of the case continues.
In June, Sandesh Patil, a cardiologist practicing at another St. Joseph hospital -- this one in London, Kentucky -- agreed to plead guilty to charging Medicaid for a stent that wasn’t medically warranted under the program’s rules. (Although both hospitals were once owned by the same parent, the one in Maryland has been sold.)
Catheterization procedures multiplied at St. Joseph in London after Patil began practicing there in 2000, when the hospital had a different name. In that year, the type of procedure used for stents was done 210 times. They climbed to 929 by 2009, state data show.
Multiple Stents
Stenting income from Medicare alone was more than a sixth of the hospital’s 2009 operating income, based on data from American Hospital Directory, a research firm. When Patil left London in 2010, catheterization procedures fell 34 percent from their 2009 high. Using the midpoint of the directory’s price range for such procedures, the decline would have cost the hospital about $15 million. David McArthur, the hospital’s spokesman, declined to comment on its revenues.
Rhonda McClure, one of Patil’s patients, had her arteries catheterized 18 times by him and his partners over four years, according to her deposition and other filings in a lawsuit she and 361 other patients have brought against Patil, St. Joseph and other doctors who practiced there. She said she received eight cardiac stents. The defendants deny the negligence and fraud allegations against them.
McClure’s deposition says a cardiologist who reviewed her case after the stents told her that scarring caused by “too many procedures” was her main problem.
Short Breath
McClure said she suffers from chest pain and shortness of breath, and has been told by her new doctor that she may need more stents and surgery to keep her coronary arteries from closing. She said she gets so tired she needs to sit and rest after walking down the stairs.
St. Joseph-London repaid Medicare $256,800 for unnecessary procedures and is cooperating with federal prosecutors, McArthur said. He said Patil was never employed by St. Joseph and lost his privileges to practice there in December 2010. Patil’s attorney said his client had no comment.
Under his plea bargain, Patil agreed to serve 30 to 37 months in federal prison. He forfeited his Kentucky medical license for five years. In 2012, he told a family court judge his monthly income was $53,300.
“Thirty-seven months is nothing for all the injuries he done for money,” McClure said.
Message Balancing
After the Courage trial shed doubt on stents’ effectiveness for stable patients, stent-implanting cardiologists felt unfairly attacked and organized a campaign to “better balance the messaging,” said Bonnie Weiner, who was president of the Society for Cardiovascular Angiography and Interventions at the time.
The society hired a public relations firm and paid it more than $300,000 a year to help publicize the benefits of stents, according to the group’s filings with the Internal Revenue Service. The firm helped launch a consumer website for SCAI, SecondsCount.org, which has published several articles, including one under the headline, “For many patients, open arteries are better than closed arteries.”
SCAI collected $2.7 million in donations for “public education” between 2008 and 2011 from stent makers Abbott Laboratories (ABT) Inc., Boston Scientific Corp. (BSX), Cordis Corp. and Medtronic Inc. (MDT), its Web site says. Manufacturers’ sales of cardiac stents were about $5.5 billion globally last year, down 5 percent from 2011, according to the Health Research International consulting firm.
High Median
Medtronic spokesman Joseph McGrath said grants to SCAI for patient education are “unrestricted,” and SCAI is solely responsible for how the funds are used. Spokesmen for Abbott, Boston Scientific and Cordis declined to comment.
Interventional cardiologists, the specialty SCAI represents, earn a median income of $562,855 a year, as compared to $207,117 for family doctors, according to Medical Group Management Association, which surveys physician practices. The interventionalists ranked 13th among 118 specialties tracked by MGMA.
Michigan Death
Mehmood Patel, a Lafayette, Louisiana, cardiologist who went to prison last year on 51 counts of charging for needless stents, made over $16 million in one three-year span, evidence in the case showed. Prosecutors said he was driven by the desire to be the busiest cardiologist in town.
He unsuccessfully argued that he used his best medical judgment in every case and lost an appeal. Patel is serving a 10-year sentence in a federal penitentiary.
Jashu Patel, an interventionalist in Jackson, Michigan, billed $2.7 million for procedures in 2007, according to a U.S. Justice Department case against him settled in July. (He is no relation to Mehmood Patel).
The suit alleged Patel implanted needless stents in at least two patients, including one that led to a blood clot that killed an unnamed woman who had reported no symptoms of reduced cardiac blood supply. A stress test showed normal blood flow, and notes in her file said she didn’t want interventions, said Julie Kovach, a cardiologist who worked with Patel and brought the case to the government’s attention.
“It was appalling,” Kovach said in an interview. “Patel coerced her into getting a stent she didn’t need, which killed her.”
False Claims
Kovach said that when she told the chief operating officer of the hospital where Patel worked about the death, the executive, Karen Chaprnka, diverted the conversation. Reached recently by e-mail through a hospital spokesman, Chaprnka said she “disagreed with the allegations made by Dr. Kovach.”
“He’s their cash cow,” said Kovach, now co-director of a clinic that treats congenital heart disease at the Detroit Medical Center. “They’re not about to turn him in.”
Patel and the hospital, Allegiance Health, agreed to pay the U.S. a total of $4 million to settle the federal charges. Kovach was awarded $760,000 as a whistle-blower under the U.S. False Claims Act. Allegiance disagreed with the allegations and settled the claims to avoid “lengthy litigation,” it said in a statement.
Patel continues to practice at the hospital and must improve record-keeping to substantiate cardiology procedures, Allegiance said. In the settlement, Patel agreed to hire a consultant to oversee treatment of his patients and an auditing firm to monitor billings. He didn’t return phone messages.
Cleveland Raid
In Ohio, Simecek, the worker at the Ford dealership, grew suspicious after his sixth stent from cardiologist Harry Persaud at the Cleveland Clinic’s Fairview Hospital in 2011. Simecek said he went for a second opinion and was told he didn’t need any of the stents. Now he said he has to take blood thinners the rest of his life.
“With the littlest cut, the blood starts running,” said Simecek. “What if I am in an auto accident?”
Persaud is under criminal investigation for health care fraud, mail fraud and money laundering, according to federal court filings. Last October, Federal Bureau of Investigation agents raided his office and removed financial records and patient files for procedures at three Cleveland-area hospitals. The government has seized $343,634 from his and his wife’s bank accounts, alleging the funds represent the proceeds of fraud related to a “significant number” of unnecessary stent procedures.
Multiple, Elongated
The Cleveland Clinic found “problems related to the use of stents in some patients” at Fairview and reported them to the government, according to spokeswoman Eileen Sheil. She would not say how many patients were affected. Persaud resigned from the hospital staff last year.
At least 64 of Persaud’s patients at St. John Medical Center in suburban Westlake received letters from the hospital saying they may have received an unnecessary stent between 2010 and 2012, according to spokesman Patrick Garmone, who said Persaud no longer practices there.
Persaud denied wrongdoing in court filings and said his stent procedures were proper. Neil Freund, his attorney in lawsuits filed by patients alleging unwarranted stents, said “it is our intent to defend these cases.” He had no comment on the federal investigation.
Final Order
In Texas, the state medical board’s final order in DeMaio’s case found that the cardiologist placed “multiple, elongated, overlapping” stents in patients in areas of “insignificant or only moderate disease.” Peterson, the retired mailman, was identified only as Patient C in the staff complaint. No patient was mentioned in the final order.
Peterson was thriving in his new career in the travel business, his wife Shirlee said. He had a heart attack in 1997, which didn’t crimp his love of travel and dance, she said. “He was an awesome man who never met a stranger,” she said.
After his death, Shirlee Peterson said a friend told her she had a cardiologist who refused to do multiple stents.
I do believe that Bruce was a guinea pig,” she said. “That was the way it was done.”
DeMaio said Peterson was extremely sick when he came to him. He said it was significant that the board’s final order didn’t use the word ”excessive” in describing his stent work. That included 31 stents stretching for 14 inches inside the arteries of Patient B in the staff complaint.
“Any patient of mine who received a full metal jacket” -- interventional cardiology’s term for such extensive work -- “would have been turned down by at least one, if not multiple surgeons,” DeMaio said. He said he doesn’t use stents as much these days because standards have changed and he doesn’t see as many seriously ill patients.
To contact the reporters on this story: Peter Waldman in San Francisco at pwaldman@bloomberg.net; David Armstrong in Boston at darmstrong16@bloomberg.net; Sydney P. Freedberg in Miami at sfreedberg@bloomberg.net
To contact the editor responsible for this story: Gary Putka at gputka@bloomberg.net